financetom
Business
financetom
/
Business
/
JP Morgan Analyst Sees Earnings Upside For Morgan Stanley Post-Q4 Beat: Details
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
JP Morgan Analyst Sees Earnings Upside For Morgan Stanley Post-Q4 Beat: Details
Jan 16, 2025 10:48 AM

JP Morgan analyst Kian Abouhossein shared views on Morgan Stanley ( MS )‘s fourth-quarter results reported today.

The bank reported an adjusted EPS of $2.22, up from $0.85 a year ago and beating the consensus of $1.70. Revenue of $16.22 billion, up 26% year over year, beat the consensus of $15.03 billion.

The analyst writes that Morgan Stanley’s Investment Banking performance is strong, with Equity S&T rising 51% year-over-year (JPM estimate +18%) to $3.3 billion, outperforming the U.S. peers.

The analyst also adds that FICC performed well, growing 35% year over year (JPM estimates +19%) versus an average of 25% among its U.S. peers.

With a Neutral rating on the stock, the analyst expects Morgan Stanley’s shares to outperform peers today.

Abouhossein expects mid-to-high single-digit % EPS upgrades to 2025 consensus but this would be partly dependent on earnings conference call.

During the conference call, the analyst anticipates questions regarding Wealth Management NII, the outlook for IB fee growth following optimistic comments from peers.

Also, the analyst expects the bank to provide outlook for share buybacks, which were in line with JP Morgan estimates expectations at $0.75 billion for the fourth quarter.

Investors can gain exposure to the stock via iShares U.S. Broker-Dealers & Securities Exchanges ETF and Invesco KBW Bank ETF ( KBWB ) .

Price Action: MS shares are up 2.57% at $133.90 at the last check Thursday.

Read Next:

Big Banks Continue To Beat Q4 Earnings As Financial ETF Takes A Breather

Image via Shutterstock.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
TransAlta Q4 Net Loss Narrows, Revenue Rises
TransAlta Q4 Net Loss Narrows, Revenue Rises
Feb 20, 2025
07:46 AM EST, 02/20/2025 (MT Newswires) -- TransAlta ( TAC ) reported a Q4 net loss Thursday of 0.22 Canadian dollars ($0.15) per share, narrowing from a loss of CA$0.27 a year earlier. An analyst polled by FactSet expected earnings of CA$0.19. Revenue for the quarter ended Dec. 31 was CA$685 million, up from CA$631 million a year earlier. The...
Repligen Q4 Adjusted Earnings Decline, Revenue Increases -- Shares Up Pre-Bell
Repligen Q4 Adjusted Earnings Decline, Revenue Increases -- Shares Up Pre-Bell
Feb 20, 2025
07:45 AM EST, 02/20/2025 (MT Newswires) -- Repligen ( RGEN ) reported Q4 adjusted earnings Thursday of $0.44 per diluted share, down from $0.48 a year earlier. Analysts polled by FactSet expected $0.41. Revenue for the quarter ended Dec. 31 was $167.5 million, compared with $166.6 million a year earlier. Analysts polled by FactSet expected $167.6 million. The company said...
HF Sinclair posts bigger-than-expected loss as refining margins shrink
HF Sinclair posts bigger-than-expected loss as refining margins shrink
Feb 20, 2025
Feb 20 (Reuters) - Refiner HF Sinclair on Thursday posted a bigger-than-expected loss for the fourth quarter, becoming the latest energy company to take a hit from weak refining margins and rising global capacity. Bigger rivals Valero Energy ( VLO ) and Marathon Petroleum ( MPC ), as well as energy heavyweights such as Exxon Mobil ( XOM ), have...
Telix Pharmaceuticals 2024 Revenue Increases; Issues 2025 Revenue Outlook
Telix Pharmaceuticals 2024 Revenue Increases; Issues 2025 Revenue Outlook
Feb 20, 2025
07:45 AM EST, 02/20/2025 (MT Newswires) -- Telix Pharmaceuticals ( TLX ) reported 2024 revenue Thursday of 783.2 million Australian dollars ($499.0 million), up from AU$502.5 million a year earlier. Analysts polled by FactSet expected AU$774.8 million. The biopharmaceutical firm said it expects 2025 revenue of AU$1.18 billion to AU$1.23 billion. Analysts surveyed by FactSet expect AU$1.09 billion. Shares of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved